WHO-EM/CTD/081/E

Report on the

Interregional meeting on leishmaniasis among neighbouring endemic countries in the Eastern Mediterranean, African and European regions

Amman, Jordan 23–25 September 2018



Report on the

Interregional meeting on leishmaniasis among neighbouring endemic countries in the Eastern Mediterranean, African and European regions

Amman, Jordan 23–25 September 2018



© World Health Organization 2019

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. [Title]. Cairo: WHO Regional Office for the Eastern Mediterranean; 2019. Licence: CC BY-NC-SA 3.0 IGO.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

CONTENTS

1.	INTRODUCTION1				
2	OVERVIEW OF CUTANEOUS AND VISCERAL LEISHMANIASIS2				
2.					
	2.1 Global overview and updated strategies for control and prevention of leishmaniasis				
	2.2 Situation of leishmaniasis control at a regional level: Eastern				
	Wedneralean Region				
	2.3 Situation of leishmaniasis control at a regional level: European Region				
	2.4 Situation of leishmaniasis control at a regional level: African Region				
	2.5. Country presentations				
3.	ENHANCING DIAGNOSIS AND TREATMENT OF CUTANEOUS AND				
	VISCERAL LEISHMANIASIS				
	3.1 Access to diagnostics and medical treatment				
	3.2 Stock management and medicines logistics				
4.	SURVEILLANCE, DATA MANAGEMENT AND REPORTING OF				
	CUTANEOUS AND VISCERAL LEISHMANIASIS				
	4.1 Global surveillance using DHIS 2				
	4.2 Progresses and challenges to implementing DHIS 2 at country level9				
5.	CONTROL OF VECTORS AND RESERVOIR HOSTS12				
	and evaluation to measure impact12				
	5.2 Passage new priorities for provention and control of leighmaniasis under the				
	universal health coverage agenda: summary of group work				
6.	ADDRESSING LEISHMANIASIS IN CRISIS SITUATIONS AND OUTBREAK				
0.	RESPONSE				
	6.1 Global- and regional-level experience in responding to outbreaks of				
	leishmaniasis				
	6.2. Country-level response to leishmaniasis outbreaks: Pakistan16				
	6.3 Country-level response to leishmaniasis outbreaks: Syrian Arab Republic17				
7.	CROSS-BORDER CHALLENGES AND AREAS OF COLLABORATION17				
0					
8.	STRENGTHENING THE CAPACITY OF HEALTH STAFF FOR				
	SKIN NEGLECTED TROPICAL DISEASES INCLUDING LEISHMANIASIS18				
9.	PREPARATION FOR GPW 13: COUNTRY SUPPORT PLANS FOR 2020–2021,				
<i>)</i> .	AND PLANNED ACTIVITIES FOR 2019				
	11 (2 1 2 1 (1 (2 1 1 1 1 1 1 2 1 0 1 2 0 1) mm.				
10.	RECOMMENDATIONS				
Ann	exes				
1.	Programme				
2.	List of participants25				
3.	Country presentations				
4.	Treatment for cutaneous leishmaniasis				
5 .	Country-level vector and reservoir control measures, Eastern Mediterranean Region38				
J.	Country-level vector and reservoir control incasures, Eastern inculterranean Region36				

WHO-EM/CTD/081/E

1. INTRODUCTION

An interregional meeting on leishmaniasis among neighbouring endemic countries in the Eastern Mediterranean, African and European regions was organized by the World Health Organization (WHO) Regional Office for the Eastern Mediterranean in Amman, Jordan, from 23 to 25 September 2018. The meeting was attended by representatives from the health ministries of Albania, Georgia, Greece, Iran (Islamic Republic of), Iraq, Jordan, Lebanon, Morocco, Pakistan, Saudi Arabia, Sudan, Syrian Arab Republic and Tunisia. Representatives from Afghanistan, Algeria and Libya were unable to attend. The Secretariat comprised staff from WHO headquarters, WHO regional offices in the Eastern Mediterranean, Africa and Europe, WHO country offices in Iraq, Pakistan, Syrian Arab Republic and Yemen, and WHO temporary advisors from Spain and Tunisia.

Dr Hoda Atta, Coordinator, Department of Communicable Disease Prevention and Control, WHO Regional Office for the Eastern Mediterranean, opened the meeting by welcoming the participants, experts, programme managers, and headquarters and country office staff, and acknowledged the importance of holding the review meeting in view of the current sociopolitical context and its related challenges for neglected tropical diseases in the three neighbouring regions of WHO.

Neglected tropical diseases are strongly associated with the Agenda for Sustainable Development, namely, target 3.3 of Sustainable Development Goal (SDG) 3 (the so-called "health goal"), that calls for ending neglected tropical disease epidemics by 2030, and SDG 1, which targets the ending of poverty in all its forms. Neglected tropical diseases are also strongly linked to universal health coverage (target 3.8), which targets providing access to health services and essential medicines. Access to medicines for neglected tropical diseases will be an indicator of the overall success of universal health coverage, for which a key principle is that "no one should be left behind".

The objectives of the interregional meeting were to:

- review epidemiology and control of leishmaniasis in countries of the Eastern Mediterranean Region, as well as neighbouring countries in the African and European regions;
- discuss the strategic elements and operational action required to enhance early diagnosis and treatment, including surveillance and data management/reporting, access to medicines and consumables, control of vectors and reservoir hosts, and capacities of health staff;
- share experiences on surveillance of leishmaniasis with emphasis on the District Health Information Software (DHIS 2) online tool;
- identify ways to address and overcome the challenges faced by countries in controlling the disease, notably in complex operational environments;
- identify cross-border issues and areas of collaboration to improve disease control;
- agree on priority research topics for leishmaniasis within the universal health coverage agenda.

WHO-EM/CTD/081/E Page 2

Eco-epidemiologically, the scope of endemic zones for cutaneous and visceral leishmaniases traverse WHO regional "borders", which highlights the importance of cross-border collaboration, and the need to include neighbouring regions in relevant discussions. The scope of the meeting aimed to cover all topics relating to leishmaniasis control, for both cutaneous and visceral leishmaniasis, as well as discuss cross-border issues with neighbouring regions. As such, the meeting covered updates on epidemiology, diagnosis, treatment, vector control, surveillance, research and emergency situations.

The neighbouring regions of Europe and Africa and their national counterparts were thanked for their participation, and encouraged to have increasingly open and collective dialogue, as they share common goals.

The programme was adopted (Annex 1) and the participants were introduced (Annex 2). The meeting was chaired by Dr El Hag; the rapporteurs were Dr Moreno Nuncio and Dr Kakar.

2. OVERVIEW OF CUTANEOUS AND VISCERAL LEISHMANIASIS

2.1 Global overview and updated strategies for control and prevention of leishmaniasis

A global overview of leishmaniasis was presented using data published in the WHO Global Health Observatory (http://apps.who.int/neglected diseases/ntddata/leishmaniasis/leishmaniasis.html). An article providing an update on the global situation, to be published 5 October 2018 in the Weekly Epidemiological Record, describes the distribution of cutaneous and visceral leishmaniasis burden among different WHO regions and trends in the reported number of new cases since 1998. With 137 772 cutaneous leishmaniasis cases, the WHO Eastern Mediterranean Region remains the region carrying the highest burden of cutaneous leishmaniasis globally, followed by the Region of the Americas with 24% of the burden. Since 1998 and up to 2015, a constant rise in the number of cutaneous leishmaniasis cases in the Eastern Mediterranean Region has been observed. Although the burden of visceral leishmaniasis is more spread out among regions, the African and South-East Asia regions suffer the highest percentage, both at 30%. A visible decline in the number of visceral leishmaniasis cases in the South-East Asia Region was also observed, while the other regions displayed fluctuating and stable trends.

Regarding progress made in control strategies, several studies and publications were highlighted and discussed. A recent study completed by Morocco to determine the appropriate interventions for effective control of leishmaniasis concluded that, despite all efforts, monitoring and control of cutaneous leishmaniasis remains challenging and that integrated vector management control with community participation is recommended as an effective strategy. Other publications included an evaluation of rapid diagnostic tests for cutaneous leishmaniasis in Morocco, which achieved a 68% sensitivity (95% confidence interval (CI): 61–74) and 94% specificity

WHO-EM/CTD/081/E Page 3

(95% CI: 91–97), and the assessment of fipronil bait orally administered to *Rhombomys opimus*, for control of fleas (Siphonaptera: Pulicidae) and phlebotomine sandflies (Diptera: Psychodidae) in Kazakhstan. The presentation concluded with an acknowledgement of the countries' individual efforts, and emphasized the importance of continuing and strengthening previously established control efforts.

2.2 Situation of leishmaniasis control at a regional level: Eastern Mediterranean Region

Dr Atta, WHO Regional Office for the Eastern Mediterranean

Both cutaneous and visceral forms of leishmaniasis are present in the Eastern Mediterranean Region, making it a significant neglected tropical disease. Regarding cutaneous leishmaniasis, both the anthroponotic form, caused by *Leishmania tropica*, and the zoonotic form, caused by *L. major* with animal reservoir hosts, are endemic in the Region. The *Framework for action on cutaneous leishmaniasis in the Eastern Mediterranean Region 2014–2018* was developed following several global and regional mandates, including resolution WHA60.13 on Control of leishmaniasis (2007), EM/RC54/R.3 on Neglected tropical diseases: an emerging public health problem in the Eastern Mediterranean Region (2007), and EM/RC40/R.7 on Leishmaniasis (1993).

Cutaneous leishmaniasis is one of the priorities in the WHO Eastern Mediterranean Region as it carries a large portion of the global burden. According to data reported in the Global Health Observatory, the Eastern Mediterranean Region reported 69.6% of the total number of cutaneous leishmaniasis cases detected worldwide in 2016 (followed by the Region of the Americas with 28.5% and the European Region with 1.6%). Of the total cases in the Region, over 90% were reported from three countries: the Syrian Arab Republic, Afghanistan and Pakistan, each of which reported more than 10 000 cases. Most of the cases are due to the anthroponotic form of the disease. Regarding visceral leishmaniasis, the Eastern Mediterranean Region carries about 19% of the global burden, with the highest number of cases reported from Sudan and Somalia.

The Region is facing many challenges - emergencies, crises situations,

预览已结束, 完整报告链接和二维码如下:

https://www.yunbaogao.cn/report/index/report?reportId=5_25289



